Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
Read original at benzingaStocks · News reference
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study
ProMIS Neurosciences announced positive interim Phase 1b trial data for its Alzheimer's drug candidate PMN310, showing zero ARIA-E.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 4:30 PM
- Checked
- Jul 28, 2026, 4:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzinga8-K filing — ProMIS Neurosciences Inc. (PMN)
Filed: 2026-08-13 AccNo: 0001104659-26-095905 Size: 246 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share
Read original at benzinga